iRhythm Technologies announced the commercial launch of its Zio monitor and Zio long-term continuous, LTCM, ambulatory ECG monitoring service in Austria, the Netherlands, Spain, and Switzerland. The Zio monitor and ZEUS system received the European Union’s CE Marking Under Medical Device Regulation, EU MDR, in December 2023. The Zio LTCM service provides up to 14 days of continuous, uninterrupted ECG monitoring, marking a significant advancement in these countries, compared to older, commonly used 24- to 48-hour Holter monitoring services. “Expanding access to our innovative Zio cardiac arrhythmia monitoring system and services for millions more people in Europe is an important milestone for iRhythm’s patient-first mission to positively impact people across the globe,” said Quentin Blackford, iRhythm President and CEO. “Our commitment extends to broadening our highly innovative digital healthcare solutions, while ensuring they are cost-effective and accessible worldwide.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
- iRhythm price target lowered to $110 from $135 at Citi
- iRhythm Technologies to Participate in Upcoming Investor Conferences in September
- iRhythm price target lowered to $110 from $120 at Baird
- iRhythm sees FY24 revenue $580M-$590M, consensus $583.5M